DR. ANDREA MARI (Orcid ID : 0000-0001-9070-5706)

DR. RICCARDO CAMPI (Ordd ID: 0000-0001-5237-0888)

DR. UMBERTO CAPITANIO (Orcid ID: 0000-0001-9225-1795)

DR. FRANCESCO PORPIGLIA (Orcid ID: 0000-0001-8567-6795)

DR. ANDREA MINERVINI (Orcid ID: 0000-0001-5140-4628)

Artide type : Original Artide

Nomogram for predicting the likelihood of postoperative surgical complications in patients treated with partial nephrectomy: a prospective multicenter observational study (the RECORd 2 project)

<sup>1</sup> Andrea Mari, <sup>1</sup> Riccardo Campi, <sup>2</sup> Riccardo Schiavina, <sup>3</sup> Daniele Amparore, <sup>4</sup> Alessandro Antonelli, <sup>5</sup> Walter Artibani, <sup>6</sup> Maurizio Barale, <sup>7</sup> Roberto Bertini, <sup>2</sup> Marco Borghesi, <sup>8</sup> Pierluigi Bove, <sup>2</sup> Eugenio Brunocilla, <sup>7</sup> Umberto Capitanio, <sup>9</sup> Luigi Da Pozzo, <sup>4</sup> Julian Daja, <sup>6</sup> Paolo Gontero, <sup>7</sup> Alessandro Larcher, <sup>10</sup> Vincenzo Li Marzi, <sup>11</sup> Nicola Longo, <sup>11</sup> Vincenzo Mirone, <sup>12</sup> Emanuele Montanari, <sup>6</sup> Francesca Pisano, <sup>3</sup> Francesco Porpiglia, <sup>4</sup> Claudio Simeone, <sup>5</sup> Salvatore Siracusano, <sup>1</sup> Riccardo Tellini, <sup>13</sup> Carlo Trombetta, <sup>14</sup> Alessandro Volpe, <sup>15</sup> Vincenzo Ficarra, <sup>1</sup> Marco Carini, <sup>1\*</sup> Andrea Minervini.

**Collaborators**: Vincenzo Altieri; Francesco Berardinelli; Antonio Celia; Elisabetta Costantini; Fabrizio Di Maida; Mario Falsaperla; Vincenzo Ficarra; Cristian Fiori; Maria Furlan; Francesco Marson; Francesco Montorsi; Giuseppe Morgia; Angelo

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bju.14680

Porreca; Marco Roscigno; Luigi Schips; Cesare Selli; Alchiede Simonato; Carlo Terrone; Giuseppe Vespasiani; Donata Villari.

- 1 Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
- 2 Department of Urology, University of Bologna, Bologna, Italy; Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy.
- 3 Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, School of Medicine, Orbassano, Turin, Italy.
- 4 Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy.
- 5 Department of Urology, Azienda Ospedaliera Universitaria Integrata (A.O.U.I.), Verona, Italy.
- 6 Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- 7 Unit of Urology, Division of Experimental Oncology, URI-Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- 8 Department of Urology, University Hospital of Tor Vergata, Rome, Italy.
- 9 Department of Urology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
- 10 Department of Urology, University of Florence, Unit of urological minimally invasive robotic surgery and renal transplantation, Careggi Hospital, Florence, Italy.

11 Department of Urology, University Federico II of Naples, Naples, Italy.

12 Department of Urology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Policlinico, University of Milan, Milan, Italy.

13 U.C.O. Clinica Urologica, Università degli Studi di Trieste, Trieste, Italy.

14 Department of Urology, Maggiore della Carità Hospital, Novara, Italia.

15 Department of Human and Paediatric Pathology; Gaetano Barresi, Urologic Section, University of Messina, Messina, Italy.

# \* Corresponding author:

Andrea Minervini MD, PhD

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.

Address: Careggi Hospital, San Luca Nuovo, Firenze. Phone: +390552758011. Fax:

+390552758014. Email: andreamine@libero.it

Article category: Urological Oncology

### **Abstract**

**Purpose:** To identify the meaningful predictors and to develop a nomogram of postoperative surgical complications in patients treated with partial nephrectomy.

Materials and Methods: We prospectively evaluated 4308 consecutive patients who had surgical treatment for renal tumors between 2013 and 2016 at 26 urological Italian centers (RECORd 2 project). A multivariable logistic regression for surgical complication was performed. A nomogram was created from the multivariable model. Internal validation processes were performed using bootstrapping with 1000 repetitions.

Results: Overall, 2584 patients undergone PN were evaluated for the final analyses. The median American Society of Anaesthesiologists (ASA) score was 2 (IQR 2-3). Patients had a cT1a stage in 72.4% of the cases. Median PADUA score was 7 (IQR 6-8). Overall, 34.3%, 27.7%, 38% of patients underwent open, laparoscopic and robotic PN. Overall and major postoperative surgical complications were recorded in 10.2% and 2.5% of patients.

At multivariable analysis, age, ASA score, clinical T2 versus T1a stage, PADUA score, preoperative anaemia, open, and laparoscopic versus robotic approach were significant predictive factors of postoperative surgical complications. We used these variables to construct a nomogram for predicting the risk of postoperative surgical complications. At decision curve analysis, the nomogram led to superior outcomes for any decision associated with a threshold probability of above 5%.

**Conclusion:** Several clinical predictors have been associated with postoperative surgical complications. We used this information to develop and internally validate a nomogram to predict such risk.

### Introduction

According to the latest American Urological Association guideline, partial nephrectomy (PN) should be preferred over radical nephrectomy (RN) for localized tumors, regardless of the surgical approach [1]. In fact, PN has comparable oncological outcomes with a better preservation of renal function and a lower rate of long-term cardiovascular events compared to RN [2,3]. Nevertheless, PN is a technical challenging procedure. Surgical complications are a prominent concern of PN as they have been reported in up to 30% of cases [4,5]. Major surgical complications are also frequent (3-6% of cases) and can be potentially life-threatening [6].

Although the urologic community expresses a general consensus that the perioperative surgical risks are justified by the theoretical long-term favourable outcome compared to RN, the risk/benefit ratio of PN is strictly related to the patients' and tumor's clinical characteristics, but also with the surgeon experience with different approaches [7]. A careful assessment of these features is paramount and should drive the treatment-decision making for patients with renal tumors. A personalised counselling tool predicting surgical complications in patients suitable for PN has not been developed yet.

The aims of the present study are: 1) to define the incidence, severity and predictors of postoperative surgical complications after PN relying on a rigorous prospectively recorded web-based database from a national collaborative project; 2) to generate a surgical nomogram to predict the likelihood of postoperative surgical complications after PN.

### Materials and methods

The Italian REgistry of COnservative and Radical Surgery for cortical renal tumor Disease (RECORD 2 Project) is a prospective observational multicentre project promoted by the Italian Society of Urology (SIU). Overall 4325 consecutive patients undergone renal surgery for cortical renal tumors at 26 urological Italian centres between January 1<sup>st</sup>, 2013 and December 31<sup>st</sup>, 2016 were included. Of these, 2584 patients underwent PN and 1712 RN, while 29 patients had missing data. Only the 2584 patients undergone PN were included in the study and formed the analytic cohort.

An online central data server was generated and centrally controlled to limit missing or wrong data inputs. All data of patients undergoing surgery were prospectively recorded by medical doctors. The database involves 6 main folders: 1) anthropometric and preoperative data; 2) imaging, indications (elective, relative and absolute) and co-morbidities; 3) intra-operative data; 4) post-operative data; 5) histological analysis 6) follow-up. Comorbidity status was evaluated by Charlson comorbidity index (CCI), physical status by the American Society of Anesthesiologists (ASA) classification system and performance status by the Eastern Cooperative Oncology Group (ECOG) score. Surgical indications were defined as elective (unilateral lesion with healthy contralateral kidney), relative (presence of diabetes, hypertension or lithiasis that could potentially affect kidney function in the future) and absolute (bilateral tumors, multiple tumors, moderate to severe CKD or tumors involving an anatomically or functionally solitary kidney). The Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) score was calculated to assess the nephrometric complexity of each case [8]. Centre caseload was defined as number of PNs per year.

Surgical postoperative complications were defined as any postoperative event caused by surgery until the 30th postoperative day (POD), altering the normal postoperative course and/or delaying discharge. The severity of complications was graded according to the modified Clavien classification [9]. Acute kidney injury (AKI) was defined as an increase in serum creatinine to ≥1.5 times from the baseline. The recommendations for the development and implementation of reporting and grading of complications after PN of the EAU panel were applied [10].

# Statistical Analysis

A univariate and multivariable logistic regression for postoperative surgical complication was performed. The area under the receiving operator characteristic (ROC) curves (AUC) was used to quantify predictive discrimination. Different ROC curves using the same set of observations were compared to assess how comorbidities, nephrometric and surgical parameters could affect the outcome within the multivariable model (*roccomp* function) [11]. A nomogram was generated from the statistically significant variables at multivariable logistic regression. Internal validation processes were performed using bootstrapping with 1000 repetitions. Calibration was assessed by comparing the predicted probabilities with the actual observed proportions on 1000 bootstrap resamples. A decision curve analysis was applied to determine whether the clinical value of the newly derived model increased the net benefit over a realistic range of threshold probabilities [12]. Statistical significance was set as p <0.05. All tests were two-sided. Analyses were carried out using STATA v.14.1 (StataCorp LP, College Station, TX).

### Results

Patients characteristics and surgical features

The preoperative clinical characteristics and the univariate analysis for postoperative surgical complication are summarised in table 1. Male patients were 64.7%. Median age was 64.6 (IQR 55-72) years. Median CCI score was 1 (IQR 0-2). A cT1a, cT1b and cT2 stage was reported in 72.4%, 24.3% and 3.3% of the patients, respectively. Median PADUA score was 7 (IQR 6-8) and scores ≥10 were registered in 15.9% of cases. Patients had relative and absolute indication to surgery in 12.1% and 3.4% of patients. The surgical features are summarised in table 2. Patients were treated in centres performing a median of 63 (IQR 41-84) PNs/year: 1876 (72.6%), 468 (18.1%) and 240 (9.3%) patients were treated in centres performing >50, 25-50 and <25 PNs/year, respectively. Open, laparoscopic and robotic approaches were planned in 886 (34.3%), 717 (27.7%) and 981 (38%) cases. Off-clamp procedures were performed in 47.6% of the cases, an enucleative strategy of resection technique was adopted in 36.1% of cases. Conversion to open approach was registered in 7/717 (0.9%) laparoscopic and 3/981 (0.3%) robotic PNs.

Postoperative surgical complications

Postoperative surgical complications were reported in 264 (10.2%) of cases. Of these, 1.9% were Clavien 1, 5.9% were Clavien 2, 1.1% Clavien 3a, 1.2% Clavien 3b and 0.2% Clavien 4a. Overall, 8.5% of patients required postoperative treatment for bleeding: 7.1% were treated with transfusions (median units transfused 2 [IQR 1-2]), 0.9% with superselective embolization and 0.5% with surgical reintervention.

Persistent urinary leakage was diagnosed in 1.1% of cases requiring prolonged maintenance of the drain and its manipulation in 0.2%, while 0.9% required urinary stenting or nephrostomy tube insertion. Two (0.1%) cases of open PN required reintervention for bowel obstruction. Four (0.2%) cases of open PN required drain position for postoperative pneumothorax. Postoperative AKI managed with pharmacological treatment was recorded in 2.2% of cases.

Multivariable models for postoperative surgical complications

At the full multivariable model, age (OR 1.01, 95% CI 1.00-1.03, p=0.03), ASA score (OR 1.281, 95% CI 1.00-1.62, p=0.046), clinical T2 versus T1a stage (OR 2.03, 95% CI 1.13-3.67, p=0.01), PADUA score (OR 1.16, 95% CI 1.05-1.25, p=0.001), preoperative anaemia (OR 2.20, 95% CI 1.58-3.05, p<0.001), open (OR 2.87, 95% CI 1.94-4.27, p<0.001), and laparoscopic (OR 1.73, 95% CI 1.13-2.64, p=0.01) versus robotic approach were significant predictive factors of postoperative surgical complications, while CCI and ECOG scores, surgical indication, baseline creatinine, centre caseload and enucleoresective strategy were not. The full model had an area under the ROC curve of 73.1%.

The area under the ROC curve slightly decreased if the comorbidity and performance status scores (72.4%, p=0.15) and if the cT stage and PADUA score (71.1%, p=0.09) were removed from the full model (Figure 1 a-b). In comparison to the full model, a reduced model without surgical approach and resection strategy reduced the area under the ROC curve to 69.6% (p<0.001) and decreased to 68.7% (p<0.001) if also centre caseload was removed (Figure 1 c-d).

## Surgical nomogram

The final nomogram included age, ASA score, preoperative anaemia, surgical indication, Clinical T stage, PADUA score, surgical approach (Figure 2a). The area under the ROC curve of the model was 72.4%. After a bootstrapping with 1000 repetitions, the model reported a bias of -0.05 and a standard error of 0.607 (95% CI -7.13, -4.75). Calibration plot focusing on nomogram performance characteristics exhibited a slight underestimation when predicted postoperative surgical complication risk was compared to >50% observed events (Figure 2b). At the decision curve analysis, the nomogram led to superior outcomes for any decision associated with a threshold probability of above 5% and showed a meaningful net benefit of the model compared to PADUA score in threshold probabilities between 5% and 30% (Figure 2c).

## **Discussion**

PN is a complex surgical intervention and the prediction of surgical complications rate, in addition to the oncologic and functional outcomes, is paramount to assess the risk/benefit ratio of PN compared to the radical treatment [13,14]. In our study, the overall postoperative surgical complication rate was 10.2% and the major surgical postoperative complication rate was 2.5%. These results represent a further demonstration of the increasing safety of this procedure over time and slightly exceed the perioperative results of the Italian registry of conservative surgery for renal tumors (RECORd 1 project) from 2008 to 2012, which reported an overall and major complication rate of 13.1% and 3.5%, respectively [4]. The overall and Clavien 3 complication rate reported in this study were also lower compared to those of the

national database of the British Association of Urological Surgeons (BAUS) reporting an overall complication rate of 17.8% and Clavien ≥3A complication rate of 5% in 1044 patients treated with PN at ten institutions from 2001 to 2012 [15]. Indeed, the higher rate of complications in this series could be related to the different era of patients' accrual and to the lower rate of minimally-invasive PNs compared to our study (41.5% vs 65.7%). Larcher and co-authors reported from the Surveillance, Epidemiology, and End Results (SEER) Medicare registry an overall complication rate of 37%, a transfusion rate of 11% and AKI in 5.8% of the cases in almost two-thousands patients treated with PN [5]. The older age and the higher rate of comorbidities of Medicare beneficiaries, together with the different characteristics of the health-care providers tracked in a population-based dataset and the different surgical era can explain such discrepancy.

We constructed a multivariable model to predict the risk of development of postoperative surgical complications after PN. Age, baseline haemoglobin, cT stage, PADUA score and planned surgical approach were significant predictive factors of postoperative surgical complications and therefore included in the model. As about patients performance status and its impact on the safety of partial nephrectomy, three different scores were included in the full multivariable model, but, interestingly, there was a trend towards significance only for two of them (ASA score [p=0.046] and ECOG score [p=0.07], while the most accurate CCI failed to reach significance at the multivariable analysis. Indeed, the development of a new proper comorbidity scale to specifically predict the outcomes after renal surgery would be helpful for patients counselling.

Patients with tumors clinically staged T2 had over a double risk of developing surgical complications compared to those with T1a tumors, while T1a and T1b tumors had a comparable rate of surgical complications (p=0.76). Indeed, the surgical feasibility of PN in patients with cT1b disease has been reported by several authors [16,17]. A recent report suggests that PN should not compromise the oncological outcome in patients with a >7 cm renal tumors even when performed with a robotic approach [18]. However, most of the surgical series comparing PN with RN reported a significantly higher blood loss and complication rates in patients treated by PN [19-22]. cT stage should be carefully considered together with the nephrometry features of the tumor: in our study, each point increase of PADUA score determined a significant increase risk of 13% of developing surgical postoperative complications. The PADUA score has been demonstrated to predict the risk of perioperative complications in patients who underwent open PN in series including mostly patients with <4 cm renal tumors [8,23]. This was confirmed also in this more comprehensive study including patients treated with minimally invasive approaches and for cT1b-T2 renal tumors.

As about centre expertise and the ways in which surgery can be performed, it was not the centre caseload, but the surgical approach that independently correlated with a reduction of surgical complications. In fact, open and laparoscopic surgery compared to robotic were the most meaningful surgical predictors of postoperative surgical complications. However, centre expertise and surgical approach are tightly interconnected in our study: among the 16/26 centres where the robotic system was available, 12 had >50 PNs per year. Conversely, the surgical technique of tumor resection lost significance at multivariable analysis. Nevertheless, the surgical variables had the strongest impact on postoperative surgical complications in our

multivariable model. Their exclusion led to a loss of clinical significance of the model (AUC 73.1% vs 68.7%, p<0.001). A possible explanations of these results are attributable to the benefits of minimally invasive surgery and to the improved dexterity and vision of robotic system, that allows a more precise dissection, a careful haemostasis and renal reconstruction with a shorter learning curve compared to laparoscopy [24]. Therefore, surgical approach might have a higher impact on predicting the likelihood of surgical complications compared to the surgical technique and centre caseload.

Interestingly, the absolute indication was not a significant predictor of postoperative surgical complications in the full model. This finding is consistent also with other multicentre [4] and high-volume-centre [25] series. Indeed, surgeons are often enticed to treat also complex renal masses with a conservative strategy in patients with imperative indication. However, this highly challenging procedure is often performed in high-volume centres by very experienced surgeons: this might explain why the surgical indication was not a significant predictor of surgical complications at multivariable analysis in our series. However, surgical indication did not reach the significance even in the multivariable reduced model n. 4 which excludes the surgical parameters and the volume centre, but it did in the multivariable model n. 2 which excluded comorbidity and performance status scores. This could be related to the not uncommon presence of comorbidities in patients with impaired renal function due to medical reasons. Indeed, further studies are needed to better address this point and PN in patients with absolute indication remains an extremely challenging procedure.

Nomograms provide a numerical estimation of risk in the form of a probability on the basis of several patient, tumor and surgical characteristics and they are currently considered the most accurate tool to predict outcomes after surgical treatment.

Numerous similar models have been published for urologic malignancies to predict oncologic outcomes [26–28], for specific treatment-decision making [24,29] and to assess the risk of surgical complications [30,31]. The internal bootstrapping was then performed to assess if the observed probability in 1000 resamples of the cohort was consistent with the prediction of the nomogram constructed using the entire cohort. The calibration plot showed an overlap of the predicted and observed probability of the surgical nomogram revealing a clinical meaningfulness of the nomogram when the observed/predicted risk was <50%. Furthermore, the decision curve analysis showed that the statistical model would improve the clinical decision-making when the predicted risk was >5%.

Despite a nomogram has been previously developed to assess the risk of complications after PN [5], this study adds a nephrometric score to the model and describes carefully all postoperative complications including their grade. A predictive tool, such this, can enable clinicians to evaluate the risk of postoperative surgical complications and might allow more accurate risk stratification on each individual case before treatment.

Despite the strengths, this study is not devoid of limitations. First, we could not determine the experience and the learning curve of each surgeon therefore the centre caseload of PN per year, was chosen as a surgical experience surrogate.

Thus, our nomogram should be interpreted in light of the lack of specific knowledge on the treating surgeon's experience and skills in PN and future studies considering this variable as a predictor of surgical complications are warranted to confirm its

impact on key PN outcomes. A conservative vs radical treatment and an enucleative vs standard PN resection were performed according to the surgeons' preference. Minimally invasive approaches were performed according to the centre availability and to the preference of the surgeons that might prefer an open approach for the management of complex renal masses despite the availability of a robotic platform. Another potential drawback of the study is the lack of external validity of the constructed nomogram. The nomogram should be tested also on other multicentre international cohorts as our findings might not be entirely generalizable to all patients undergoing PN. However, the internal validation was performed on the largest nation-based prospective database on PN available so far. Indeed, the high-quality report of outcomes was guaranteed by the rigorous control of data prospectively inserted on the internet-based platform only by medical doctors from the participating centres. Finally, this nomogram is not meant to guide the decision to perform PN vs RN in individual patients with localized renal masses but rather to provide an estimate of the likelihood of postoperative surgical complications according to specific patient-, tumor- and surgery-related variables to assist clinical decision making in everyday practice.

This study offers several opportunities for future research in this field. Indeed, multicentre prospective studies should 1) provide external validation of our nomogram in different clinical scenario; 2) develop a novel physical status score specific for PN to assess the real impact of those comorbidities that affect perioperative outcome in patients treated with conservative surgery; 3) integrate our nomogram in a more comprehensive decision-making tool to individualise selection strategy of PN vs RN in patients eligible for surgical treatment of PN.

Conclusions

Surgical complications are a not-negligible aspect to consider for the treatment-

decision making for patients with localized renal tumors with a 10.2% and 2.5% rate

of overall and major postoperative surgical complications. We developed a surgical

nomogram including age, ASA score, ECOG score, preoperative anaemia and

creatinine, surgical indication, clinical T stage, PADUA score, surgical approach, to

accurately predict the risk of surgical complications in patients with localized renal

tumors.

**Ethical approval** 

The study was first approved by the Ethical Committee of the leading Centre of the

RECORd project (Department of Urology, University of Florence, Careggi Hospital,

Florence, Italy) and then by all Ethical Committees of all Centres participating in the

project.

Conflict of Interest: None

Funding: None

Table and Figure legends

**Table 1:** Preoperative characteristics of 2584 patients treated with partial

nephrectomy for renal tumors and univariate analysis for postoperative surgical

complications.

**Table 2:** Intraoperative characteristics of 2584 patients treated with partial nephrectomy for renal tumors and univariable analysis for postoperative surgical complications.

**Table 3:** Multivariable logistic regression analyses of postoperative surgical complications adjusting for preoperative and surgical variables in 2584 patients treated with PN for renal tumors. The reduced model n. 1 exclude the comorbidity and physical status scores from the regression analysis. The reduced model n. 2 exclude the PADUA score and clinical T stage from the regression analysis. The reduced model n. 3 exclude the surgical approach and technique from the regression analysis. The reduced model n. 4 exclude the surgical approach from the regression analysis.

Legend: ASA, American Society of Anesthesiologists; CCI, Charlson comorbidity index; ECOG, eastern cooperative oncology group; LPN, laparoscopic partial nephrectomy; OPN, open partial nephrectomy; PN, partial nephrectomy; RAPN, robot-assisted partial nephrectomy; SE, simple enucleation.

**Figure 1 a-d.** Comparison of ROC areas of full versus reduced logistic regression models. A) Comparison of the full model versus the reduced model n. 1 excluding the Charlson, ASA and ECOG scores from the regression analysis. B) Comparison of the full model versus the reduced model n. 2 excluding the PADUA score and clinical T stage from the regression analysis. C) Comparison of the full model versus the reduced model n. 3 exclude the surgical approach from the regression analysis.

[1] [3]

D) Comparison of the full model versus the reduced model n. 4 exclude the surgical approach and technique from the regression analysis.

**Figure 2:** A) Surgical nomogram for predicting postoperative surgical complications in patients undergoing partial nephrectomy for renal tumors. B) Calibration plot of the actual versus predicted probability of the surgical nomogram for predicting postoperative surgical complications evaluated by 1000 bootstrap resamples. C) Decision curve analysis for the evaluation of the clinical net benefit using the surgical nomogram and PADUA score for detecting postoperative surgical complications.

# **Conflicts of interest**

None declared

## References

- [1] Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol 2017. doi:10.1016/j.juro.2017.04.100.
- [2] Zabell J, Isharwal S, Dong W, Abraham J, Wu J, Suk-Ouichai C, et al. Acute Kidney Injury after Partial Nephrectomy in Solitary Kidneys: Impact on Longterm Stability of Renal Function. J Urol 2018. doi:10.1016/j.juro.2018.07.042.
- [3] Antonelli A, Mari A, Longo N, Novara G, Porpiglia F, Schiavina R, et al. Role of Clinical and Surgical Factors for the Prediction of Immediate, Early and Late

[4] [6] [8] Functional Results, and its Relationship with Cardiovascular Outcome after Partial Nephrectomy: Results from the Prospective Multicenter RECORd 1 Project. J Urol 2018;199. doi:10.1016/j.juro.2017.11.065.

- Mari A, Antonelli A, Bertolo R, Bianchi G, Borghesi M, Ficarra V, et al.

  Predictive factors of overall and major postoperative complications after partial nephrectomy: Results from a multicenter prospective study (The RECORd 1 project). Eur J Surg Oncol 2017;43:823–30. doi:10.1016/j.ejso.2016.10.016.
- [5] Larcher A, Fossati N, Tian Z, Boehm K, Meskawi M, Valdivieso R, et al.

  Prediction of Complications Following Partial Nephrectomy: Implications for Ablative Techniques Candidates. Eur Urol 2016;69:676–82.

  doi:10.1016/j.eururo.2015.07.003.
- [6] Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol 2016;196:989–99.

  doi:10.1016/j.juro.2016.04.081.
  - Parker D, Kutikov A, Uzzo RG, Smaldone MC. Understanding Chronic Kidney
    Disease of Surgical Versus Medical Origin: The Missing Link to the Partial
    Versus Radical Nephrectomy Debate? Eur Urol 2015;68:1004–6.
    doi:10.1016/j.eururo.2015.06.001.
- [8] Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al.

  Preoperative aspects and dimensions used for an anatomical (PADUA)

  classification of renal tumours in patients who are candidates for nephron
  sparing surgery. Eur Urol 2009;56:786–93. doi:10.1016/j.eururo.2009.07.040.

- [9] Dindo D, Clavien P-A. Quality assessment of partial nephrectomy complications reporting: "time to get the head out of the sand". Eur Urol 2014;66:527–8. doi:10.1016/j.eururo.2014.04.013.
- [10] Mitropoulos D, Artibani W, Biyani CS, Bjerggaard Jensen J, Remzi M, Rouprêt M, et al. Quality Assessment of Partial Nephrectomy Complications Reporting Using EAU Standardised Quality Criteria. Eur Urol 2014;66:522–6. doi:10.1016/j.eururo.2014.02.004.
- [11] Cleves MA. From the help desk: Comparing areas under receiver operating characteristic curves from two or more probit or logit models. Stata J 2002;2:301–13.
- [12] Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565–74.

  doi:10.1177/0272989X06295361.
- [13] Cacciamani G, Gill TS, Medina L, Ashrafi A, Winter M, Sotelo R, et al. Impact of Host Factors on Robotic Partial Nephrectomy Outcomes: Comprehensive Systematic Review and Meta-Analysis. J Urol 2018.

  doi:10.1016/j.juro.2018.04.079.
- [14] Cacciamani GE, Medina LG, Gill T, Abreu A, Sotelo R, Artibani W, et al.
  Impact of Surgical Factors on Robotic Partial Nephrectomy Outcomes:
  Comprehensive Systematic Review and Meta-Analysis. J Urol 2018;200:258–74. doi:10.1016/j.juro.2017.12.086.
- [15] Fernando A, Fowler S, O'Brien T. Nephron-sparing surgery across a nation outcomes from the British Association of Urological Surgeons 2012 national

partial nephrectomy audit. BJU Int 2016;117:874–82. doi:10.1111/bju.13353.

- [16] Porpiglia F, Mari A, Bertolo R, Antonelli A, Bianchi G, Fidanza F, et al. Partial Nephrectomy in Clinical T1b Renal Tumors: Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted Approach (the RECORd Project).

  Urology 2016;89:45–51. doi:10.1016/j.urology.2015.08.049.
- [17] Ficarra V, Bhayani S, Porter J, Buffi N, Lee R, Cestari A, et al. Robot-assisted partial nephrectomy for renal tumors larger than 4 cm: results of a multicenter, international series. World J Urol 2012;30:665–70. doi:10.1007/s00345-012-0943-9.
- [18] Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, et al.

  Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal

  Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol

  2018. doi:10.1016/j.eururo.2018.05.004.
- [19] Kopp RP, Liss MA, Mehrazin R, Wang S, Lee HJ, Jabaji R, et al. Analysis of Renal Functional Outcomes after Radical or Partial Nephrectomy for Renal Masses ≥7 cm Using the RENAL Score. Urology 2015;86:312–9. doi:10.1016/j.urology.2015.02.067.
- [20] Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int 2007;100:1235–9. doi:10.1111/j.1464-410X.2007.07225.x.
- [21] Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal

Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606–17. doi:10.1016/j.eururo.2016.08.060.

- [22] Laguna MP. Re: Partial Nephrectomy versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. J Urol 2017;198:1204–6. doi:10.1016/j.juro.2017.09.050.
- [23] Minervini A, Vittori G, Salvi M, Sebastianelli A, Tuccio A, Siena G, et al.

  Analysis of surgical complications of renal tumor enucleation with standardized instruments and external validation of PADUA classification. Ann Surg Oncol 2013;20:1729–36. doi:10.1245/s10434-012-2801-9.
- [24] Shah PH, Alom MA, Leibovich BC, Thompson RH, Uzzo RG, Kavoussi LR, et al. The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. J Urol 2018. doi:10.1016/j.juro.2018.05.081.
- [25] Heinze A, Larcher A, Umari P, Fossati N, Piccolo J, De Groote R, et al.

  Assessing perioperative, functional and oncological outcomes of patients with imperative versus elective indications for robot-assisted partial nephrectomy:

  Results from a high-volume center. Int J Urol 2018;25:826–31.

  doi:10.1111/iju.13754.
- [26] Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967–72. doi:10.1200/JCO.2005.05.3884.
- [27] Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, et al. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol 2017;198:810–6.

doi:10.1016/j.juro.2017.04.066.

- [28] Krabbe L-M, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, et al. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol 2017;197:580–9. doi:10.1016/j.juro.2016.09.078.
- [29] Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell'Oglio P, Bravi CA, et al.

  Development and Internal Validation of a Novel Model to Identify the

  Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

  Eur Urol 2017;72:632–40. doi:10.1016/j.eururo.2017.03.049.
- [30] Raman JD, Lin Y-K, Shariat SF, Krabbe L-M, Margulis V, Arnouk A, et al.

  Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. BJU Int 2017;119:268–75. doi:10.1111/bju.13556.
- [31] Haddad AQ, Leibovich BC, Abel EJ, Luo J-H, Krabbe L-M, Thompson RH, et al. Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. Urol Oncol 2015;33:388.e1-9.

Preoperativ	Descript	ive analysis	Univariate analysis for postoperative complications			
		No. of	patients*	Odd ratio (95% CI)	р	
Gender N	/lale	1671	64.7%	1.27 (0.97-1.65)	0.08	
F	emale	913	35.3%	1.00 (reference)	5	
Age (years)		64.6	54.9-72.2	1.03 (1.02-1.04)	<0.001	
BMI (kg/m^2)		25.8	23.7-28.7	0.98 (0.95-1.01)	0.19	
ECOG r	nedian IQR	0	0-1	1.14 (1.08-1.13)	<0.001	
Score	• ≥1	737	28.5%	1.73 (1.33-2.27)	<0.001	
ASA r	nedian IQR	2	2-3	1.97 (1.61-2.42)	<0.001	
Score	• ≥3	700	27.1%			
CCI score		1	0-2	1.19 (1.10-1.29)	<0.001	
AA-CCI score		4	2.5-5	1.18 (1.11-1.26)	<0.001	
Surgical indicati	on				0.02	
	<ul> <li>Elective</li> </ul>	2122	82.1%	1.00 (reference)		
	<ul> <li>Relative</li> </ul>	372	14.4%	1.12 (0.78-1.60)	0.55	
	<ul> <li>Imperative</li> </ul>	90	3.5%	2.27 (1.27-4.07)	0.006	
Tumor	<ul> <li>Right</li> </ul>	1316	50.9%	1.12 (0.87-1.45)	0.39	
side, n. %	• Left	1268	49.1%	1.00 (reference)		
Clinical T, n. %					0.001	
	• T1a	1872	72.4%	1.00 (reference)	0.001	
	• T1b	628	24.3%	1.17 (0.87-1.58)	0.29	
	• T2	84	3.3%	2.78 (1.61-4.81)	<0.001	
Multiple ipsilater	al lesion n. %	152	5.9%	1.61 (0.94-2.73)	0.08	
Tumor growth p	attern	152	5.570	1.01 (0.94-2.73)	0.54	
	≥50% Exophytic	1444	55.9%	1.00 (reference)	0.04	
	<50% Exophytic	933	36.1%	1.14 (0.87-1.50)	0.34	
	Entirely endophytic	207	8.0%	1.21 (0.76-1.94)	0.42	
Tumor location	relative to the polar line (PL)			,	0.009	
	Entirely above PL	1505	58.2%	1.00 (reference)		
	≤50% crosses PL	616	23.8%	1.32 (0.90-1.95)	0.15	
	<ul> <li>&gt;50% crosses PL</li> </ul>	463	17.9%	1.55 (1.17-2.05)	0.002	
Nearingness to	the collecting system				<0.0001	
-America	• ≥7	1332	51.5%	1.00 (reference)		
	<ul><li>&gt;4 but &lt;7</li></ul>	884	34.2%	2.16 (1.57-2.96)	<0.0001	
	• ≤4	368	14.2%	1.58 (1.10-2.27)	0.01	
PADUA score, r	nedian IQR	7.0	6.0-8.0	1.16 (1.07-1.26)	<0.0001	
RENAL score, n	nedian IQR	6.0	5.0-7.0	1.18 (1.09-1.26)	<0.0001	
PADUA score o	omplexity index				0,001	
	• 6-7	1274	49.3%	1.00 (reference)	-,	
	• 8-9	900	34.8%	1.37 (1.02-1.84)	0.035	
	• ≥10	410	15.9%	1.91 (1.35-2.69)	<0.0001	
Baseline hemog	lobin (g/dL), median (IQR)	14.2	13.2-15.1	0.72 (0.66-0.78)	<0.0001	

Preoperative anaemia ^ n. %	326	12.0%	3.06 (2.28-4.13)	<0.0001
Baseline creatinine (mg/dL), median (IQR)	0.9	0.8-1.0	1.81 (1.39-2.39)	<0.0001
Baseline eGFR (mL/min), median IQR	85.8	69.9-100.4	0.99 (0.98-0.99)	<0.0001

<sup>\*</sup>Number and percentage, and median and interquartile range are reported for nominal and continuous variables.

**Table 1:** Preoperative characteristics of 2584 patients treated with partial nephrectomy for renal tumors and univariate analysis for postoperative surgical complications.


<sup>^</sup>Anaemia was defined as haemoglobin under the threshold of 12 g/dL and 13 g/dL in women and men, respectively.

Intraoperative characteristics (n=2584)	Descriptive	analysis	Univariate analysis for postoperative complications			
	No. of pat	tients*	Odd ratio (95% CI)	p		
Open approach	886	34.3%	3.74 (2.67-5.23)	<0.0001		
<ul> <li>Transperitoneal</li> </ul>	146	16.5%				
<ul> <li>Retroperitoneal</li> </ul>	740	83.5%				
Laparoscopic approach	717	27.7%	1.71 (1.16-2.52)	0.01		
<ul> <li>Transperitoneal</li> </ul>	443	61.8%				
<ul> <li>Retroperitoneal</li> </ul>	274	38.2%				
Robotic approach	981	38.0%	1.0 (reference)			
<ul> <li>Transperitoneal</li> </ul>	847	86.3%				
<ul> <li>Retroperitoneal</li> </ul>	134	13.7%				
Centre caseload	63	41-84	1.02 (1.01-1.03)	<0.0001		
Type of resection						
<ul> <li>Enucleation</li> </ul>	934	36.1%	1.00 (reference)			
Standard PN	1650	63.9%	1.95 (1.45-2.64)	<0.0001		
Haemostatics on tumor renal bed	2176	84.2%	1.00 (reference)	0.55		
<ul> <li>Application</li> </ul>	408	15.8%	1.10 (0.79-1.56)	0.00		
<ul> <li>No application</li> </ul>	400	10.070	1.10 (0.70-1.00)			
Renorraphy on tumor renal bed						
<ul> <li>Used</li> </ul>	2191	84.8%	1.00 (reference)	0.09		
Not used	393	15.2%	1.39 (0.94-2.06)			
Pedicle clamping, n. %						
On-clamp	1353	52.4%	1.00 (reference)			
• En bloc	301	22.2%				
<ul> <li>Arterial</li> </ul>	1052	87.8%				
Off-clamp	1231	47.6%	1.11 (0.85-1.43)	0.45		


**Table 2:** Intraoperative characteristics of 2584 patients treated with partial nephrectomy for renal tumors and univariable analysis for postoperative surgical complications.


		Full model			Reduced model n. 1			n analysis for postoperat Reduced model n. 2			Reduced model n. 3				duced mod	el n. 4
		OR	95%CI	p-value	OR	95%CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95%CI	p-value
Age (conti	nuous)	1.01	1.00-1.03	0.034	1.02	1.01-1.03	0.001	1.01	0.99-1.02	0.11	1.01	1.00-1.02	0.02	1.01	1.00-1.03	0.02
ASA score (continuou		1.28	1.00-1.62	0.046		8		1.28	1.00-1.62	0.04	1.48	1.17-1.86	<0.001	1.44	1.13-1.81	0.002
ECOG sco		1.21	0.98-1.47	0.071		19		1.21	0.99-1.47	0.07	1.13	0.93-1.38	0.19	1.15	0.94-1.41	0.15
CCI score (continuou	s)	1.01	0.92-1.12	0.733				1.02	0.92-1.11	0.80	1.03	0.93-1.14	0.59	1.03	0.93-1.13	0.56
Surgical Indication				0.66						0.68			0.47			0.36
	Elective	1.00 (ref.)			1.00 (ref.)			1.00 (ref.)			1.00 (ref.)			1.00 (ref.)		
	Relative	0.79	0.51-1.21	0.28	0.82	0.54-1.25	0.36	0.87	0.57-1.32	0.52	0.70	0.47-1.07	0.11	0.74	0.52-1.14	0.17
	Absolute	1.48	0.80-2.73	0.22	2.11	1.18-3.78	0.01	1.49	0.81-2.75	0.19	1.56	0.85-2.87	0.15	1.59	0.86-2.93	0.13
Clinical T	i e			0.04			0.03						0.04			0.02
	T1a	1.00 (ref.)			1.00 (ref.)				1.00 (ref.)			1.00 (ref.)				
	T1b	1.17	0.85-1.58	0.33	1.18	0.86-1.60	0.30			-	1.16	0.85-1.58	0.76	1.17	0.86-1.60	0.30
	T2	2.03	1.13-3.67	0.01	2.12	1.18-3.79	0.01				2.23	1.24-4.00	0.01	2.22	1.24-3.98	0.01
PADUA So		1.16	1.05-1.25	0.001	1.15	1.03-1.25	0.002		Ai s		1.18	1.08-1.28	<0.001	1.17	1.07-1.27	<0.001
Preoperati	ve anaemia	2.20	1.58-3.05	<0.001	2.34	1.69-3.24	<0.001	2.29	1.66-3.16	<0.001	2.29	1.66-3.16	<0.001	2.27	1.64-3.14	<0.001
Baseline C (continuou		1.26	0.92-1.72	0.14	1.36	1.00-1.83	0.04	1.23	0.90-1.67	0.19	1.19	0.87-1.61	0.27	1.28	0.87-1.75	0.12
Centre cas (PN/year)	eload	0.993	0.98-0.997	0.278	0.99	0.99-1.00	0.27	0.99	0.99-1.00	0.57	0.99	0.99-1.00	0.001			
Surgical				<0.001			<0.001			<0.001						
approach	OPN	2.87	1.94-4.27	<0.001	3.10	1.20-2.76	<0.00	3.08	2.07-4.58	<0.001						
	LPN	1.73	1.13-2.64	0.011	1.81	1.20-2.75	0.005	1.72	1.12-2.63	0.01						- 10
	RAPN	1.00 (re	ef.)		1.00 (r	ef.)		1.00 (	ef.)					- 7.		
Standard F	PN vs SE	1.02	0.72-1.45	0.91	1 04	0.73-1.47	0.53	1.12	0.79-1.60	0.52				_		

**Table 3:** Multivariable logistic regression analyses of postoperative surgical complications adjusting for preoperative and surgical variables in 2584 patients treated with PN for renal tumors. The reduced model n. 1 exclude the comorbidity and physical status scores from the regression analysis. The reduced model n. 2 exclude the PADUA score and clinical T stage from the regression analysis. The reduced model n. 3 exclude the surgical approach and technique from the regression analysis. The reduced model n. 4 exclude the surgical approach from the regression analysis.



**Figure 1 a-d.** Comparison of ROC areas of full versus reduced logistic regression models. A) Comparison of the full model versus the reduced model n. 1 excluding the Charlson, ASA and ECOG scores from the regression analysis. B) Comparison of the full model versus the reduced model n. 2 excluding the PADUA score and clinical T stage from the regression analysis. C) Comparison of the full model versus the reduced model n. 3 exclude the surgical approach from the regression analysis. D) Comparison of the full model versus the reduced model n. 4 exclude the surgical approach and technique from the regression analysis.








Figure 2: A) Surgical nomogram for predicting postoperative surgical complications in patients undergoing partial nephrectomy for renal tumors. B) Calibration plot of the actual versus predicted probability of the surgical nomogram for predicting postoperative surgical complications evaluated by 1000 bootstrap resamples. C) Decision curve analysis for the evaluation of the clinical net benefit using the surgical nomogram and PADUA score for detecting postop erative surgical complications.